STOCK TITAN

DEFENCE THERAPEUTICS A - $DTCFF STOCK NEWS

Welcome to our dedicated page for DEFENCE THERAPEUTICS A news (Ticker: $DTCFF), a resource for investors and traders seeking the latest updates and insights on DEFENCE THERAPEUTICS A stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DEFENCE THERAPEUTICS A's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DEFENCE THERAPEUTICS A's position in the market.

Rhea-AI Summary
Defence Therapeutics Inc. to participate in Festival of Biologics in Basel, Switzerland
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Defence Therapeutics announces successful results in its encapsulation strategy, with antibody response twice as potent as standard mRNA LNPs. The company plans to conduct additional tests to optimize its mRNA vaccine pipeline. The mRNA therapeutics market is projected to reach $137.59 billion by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Defence Therapeutics Inc. has entered into a service agreement with Native Ads Inc. for a marketing campaign with a total retainer of up to US$250,000. 75% of the campaign budget will be allocated to cost per click costs, media buying, and content distribution, while 25% will be allocated for content creation, web development, and advertising creative development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Defence Therapeutics continues to bring innovative strategies targeting immune-oncology indications. Their Accum® technology enhances bio-drug efficacy against cancer. ADCs improved potency by 20-100 folds. Partnership with Orano for next-gen ADC therapies. Dual acting vaccine shows 70-100% survival rate. ARM vaccine demonstrates high cure rates in lymphoma and melanoma. AccuTOXTM program halts pre-established cancers and activates immune response. IND filing expected in Q4 2023. Global oncology market valued at USD 208B in 2022, projected to reach USD 628B by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Defence Therapeutics to be featured on Viewpoint, a national educational TV show, highlighting breakthroughs in biotechnology and therapeutics innovations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.05%
Tags
none
-
Rhea-AI Summary
Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) successfully reached the first milestone in the Collaboration Agreement with Orano Support SAS to develop next-generation radio-immunoconjugates using Defence's intracellular targeting technology. The milestone involves synthesizing the AccuTOXTM peptide containing the DOTA chelator and the Azide moiety. The company aims to develop novel radio-based therapies with higher specificity and selectivity, ensuring increased therapeutic efficacy with lower adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.49%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
DEFENCE THERAPEUTICS A

OTC:DTCFF

DTCFF Rankings

DTCFF Stock Data

50.46M
42.55M
4.73%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Vancouver